Predict your next investment

Corporation
HEALTHCARE | Drug Development
briibio.com

See what CB Insights has to offer

Founded Year

2018

Stage

IPO | IPO

Total Raised

$415M

Date of IPO

7/13/2021

Market Cap

16.21B

About Brii BioSciences

Brii BioSciences (02137.HK) is a developer of new medicines exclusively for the Chinese market, committed to serving patients' needs and improving public health in China. The company aims to accelerate the development, commercialization, and delivery of breakthrough infectious disease medicines in China through partnerships, research and development, and the application of digital and data insight.

Brii BioSciences Headquarter Location

One City Center 110 Corcoran Street, Office 05-130

Durham, North Carolina, 27701,

United States

Latest Brii BioSciences News

Qpex Biopharma Announces Progress on Three Clinical Stage Programs for Antibiotic-Resistant Pathogens and Corporate Update

Jan 19, 2022

Oral and IV products based on xeruborbactam (formerly known as QPX7728), and QPX9003 are advancing in clinical studies All three products have received Qualified Infectious Disease Product Designation (QIDP) from the U.S. Food and Drug Administration (FDA) for multiple potential indications The Biomedical Advanced Research and Development Authority (BARDA) exercised a $15M option in 2021 to support continued clinical advancement of pipeline products January 19, 2022 08:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )-- Qpex Biopharma, Inc. , (Qpex) a clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced continued clinical progress of its entire pipeline and highlights the company’s strategic advancements. “The company made superb progress in filing three Investigational New Drug applications with the U.S. FDA within a seven-month period and made extensive progress in OMNIvance®, ORAvance, and QPX9003 clinical programs in 2021, positioning us for multiple data catalysts in 2022,” said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma. “Receipt of QIDP designations for all products from the FDA and progressing our partnerships further enables us to bring important therapies for antibiotic-resistant pathogens to patients.” OMNIvance® (IV) and ORAvance™ (oral) are investigational products based on Qpex’s ultra-broad-spectrum beta-lactamase inhibitor xeruborbactam (formerly known as QPX7728). These products and QPX9003 (a novel synthetic polymyxin antibiotic) have each been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA). QIDP designation is granted by the FDA for product candidates that have the potential to treat life-threatening infections due to certain qualifying pathogens, including multi-drug resistant gram-negative pathogens. Products that receive QIDP designation may receive certain incentives, such as regulatory exclusivity extensions, and eligibility for fast-track designation. The QIDP designation received by all three Qpex products include multiple potential indications, including treatment of complicated urinary tract infections and ventilator-associated pneumonia. The company also announced the exercise of a $15M option by the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response based on achievement of milestones and of its current partnership for advanced development of the company’s three clinical programs. “In addition to these milestones,” Dudley continued, “Qpex scientists published 10 peer-reviewed articles in high-impact scientific journals over the last 12 months on our ultra-broad-spectrum beta-lactamase inhibitor, xeruborbactam. These publications, along with other analyses from external experts, consistently recognize the best-in-class microbiological properties of xeruborbactam (QPX7728).” About the Qpex Biopharma Pipeline Qpex Biopharma has three clinical-stage programs focused on the treatment of extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing pathogens that the CDC considers serious or urgent antimicrobial resistance threats, including Acinetobacter spp., Pseudomonas aeruginosa, and Enterobacterales. The World Health Organization (WHO) has prioritized development of new treatments for these pathogens. Qpex’s clinical-stage portfolio comprehensively addresses patient needs in both the inpatient and outpatient settings and includes: OMNIvance®: an IV-administered xeruborbactam-based product with best-in-class coverage of key pathogens, including carbapenem-resistant Acinetobacter, Enterobacterales and Pseudomonas. ORAvance™: an orally-administered combination product that delivers xeruborbactam to treat infections that occur in the outpatient and community setting caused by drug-resistant gram-negative bacteria, including fluoroquinolone-, cephalosporin-, or carbapenem-resistant Enterobacterales. QPX9003: a next-generation, IV-administered synthetic polymyxin with an enhanced therapeutic profile designed to address highly drug-resistant infections caused by Pseudomonas and Acinetobacter. About Qpex and BARDA Partnership Qpex scientists and clinicians have an extensive track-record of successfully working in public-private partnerships, including a partnership with BARDA that led to the first approved antibiotic drug product under that program in 2017. Qpex’s current collaboration with BARDA is focused on advancing a portfolio of three novel antibiotic products, including the xeruborbactam-based products OMNIvance and ORAvance, and the novel synthetic polymyxin QPX9003. The development of the products in Qpex’s portfolio is funded in whole or in part with federal funds from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, BARDA, under OTA number HHSO100201600026C. To date, BARDA has awarded $82 million and provided technical support. If all options are awarded, the agreement would provide up to $132 million in support for the development of a portfolio of new antibiotics to fight drug-resistant gram-negative infections. About Qpex Biopharma Qpex Biopharma, Inc. is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care across both inpatient and outpatient settings. Advancing a robust portfolio of best-in-class, clinical-stage products, the company’s lead program are based on xeruborbactam, a novel ultra-broad-spectrum beta-lactamase inhibitor discovered by Qpex scientists. The company currently has a partnership with BARDA to advance its portfolio and a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China. For more information, please visit www.qpexbio.com and follow us on Twitter and LinkedIn . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Brii BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Brii BioSciences is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Digital Health

12,256 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Brii BioSciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Brii BioSciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.